Johnson & Johnson (JNJ) Revenue — Quarter Ended Dec 31, 2023
Revenue for the quarter increased compared to both the prior quarter and the same quarter last year. The company continues to operate through its Innovative Medicine and MedTech segments following the separation of its Consumer Health business.
Key takeaway
Quarter ended Dec 31, 2023 · FY2023 FY
Revenue for the quarter increased compared to both the prior quarter and the same quarter last year. The company continues to operate through its Innovative Medicine and MedTech segments following the separation of its Consumer Health business.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$21.4B
Revenue reported for this quarter.
Quarter-over-quarter
+0.2%
Change from the immediately preceding quarter.
Year-over-year
+7.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$85.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Apr 2, 2023 | $20.9B | +5.3% |
| Jul 2, 2023 | $21.5B | -22.0% |
| Oct 1, 2023 | $21.4B | +69.4% |
| Dec 31, 2023 | $21.4B | +7.3% |
Revenue performance
Revenue growth was modest on a sequential basis, while the year-over-year comparison showed solid improvement.
Quarterly comparison
Compared with the immediately preceding quarter, revenue edged higher. Compared with the same quarter one year earlier, revenue was notably stronger.
What to watch
Monitor how revenue trends evolve following the separation of the Consumer Health business earlier in the fiscal year.